Hormone replacement therapy and prevention of chronic conditions

References

• Oldenhave A, Jaszmann LT, Haspels AA, Everaerd WT. Impact of climacteric on well being. A survey based on 5213 women 39–60 years old. Am J Obstet Gynecol 1993;168:772–80
   Web of Science ®Google Scholar
• Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197–214
   PubMed Web of Science ®Google Scholar
• Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA. Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 1993;168:765–71
   Google Scholar
• Riggs BL, Wahner HW, Dunn WL, et al. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 1981;67:328–35
   PubMed Web of Science ®Google Scholar
• Nilas L, Christiansen C. The pathophysiology of peri- and postmenopausal bone loss. Br J Obstet Gynaecol 1989;96:580–7
   PubMedGoogle Scholar
• Gambacciani M, Spinetti A, De Simone L, et al. The relative contribution of menopause and aging to postmenopausal vertebral osteopenia. J Clin Endocrinol Metab 1993;77:1148–52
   PubMed Web of Science ®Google Scholar
• Cauley JA, Seeley DG, Ensrud K, et al. Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9–16
   PubMed Web of Science ®Google Scholar
• Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891–7
   PubMed Web of Science ®Google Scholar
• Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985;7:80–104
   Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA, Willet WC. Postmenopausal estrogen therapy and cardiovascular disease: 10-years from the Nursers’ Health Study. N Engl J Med 1991;325:756–62
   PubMed Web of Science ®Google Scholar
• Ross RK, Paganini-Hill A, Mack TM. Menopausal oestrogen therapy and protection from death from ischeamic heart disease. Lancet 1981;18:858–62
   Google Scholar
• Rosenberg L, Armstrong B, Phil D, Jick H. Myocardial infarction and estrogen therapy in postmenopausal women. N Engl J Med 1976;294:1256–9
   PubMed Web of Science ®Google Scholar
• Henderson BE, Ross RK, Paganini-Hill A, Mach TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986;154:1181–6
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133–6
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Lindsay D, Rosano GMC, Poole-Wilson PA. Angina and normal coronary arteries in women: gynecologic findings. Am J Obstet Gynecol 1992;167:467–72
   PubMed Web of Science ®Google Scholar
• Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557–62
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force Recommendation Statement. JAMA 2017;318:2224–33
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. Clin Endocrinol Metab 2010;95:s1–s66
   Google Scholar
• Baber RJ, Panay N, Fenton A; the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 24:728–53
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Biglia N, Cagnacci A, et al. Italian Menopause Society (SIM). Menopause and hormone replacement therapy: the 2017 recommendations of the Italian Menopause Society. Minerva Ginecol 2018;70:27–34
   PubMed Web of Science ®Google Scholar
• Langer RD, Simon JA, Pines A, et al. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Climacteric 2017;20:402–13
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 2015;100:4588–94
   PubMed Web of Science ®Google Scholar
• Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, et al. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause 2018;25:375–9
   PubMed Web of Science ®Google Scholar
• Gambacciani M. HRT misuse and the osteoporosis epidemic. Climacteric 2012;15:10–11
   PubMed Web of Science ®Google Scholar
• Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044–9
   PubMed Web of Science ®Google Scholar
• Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987;70:289–93
   PubMed Web of Science ®Google Scholar
• Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102–9
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988;297:519–22
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861–7
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37
   PubMed Web of Science ®Google Scholar
• Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestin replacement. BJOG 1992;99:821
   Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–41
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: meta-analysis. J Gen Intern Med 2004;19:791–804
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363–6
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;12:1016–22
   Web of Science ®Google Scholar
• Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. 1. Comparison of therapeutic efficacy. J Am Geriatr Soc 2013;61:1005–10
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. 2. Comparative risks. J Am Geriatr Soc 2013;61:1011–18
   PubMed Web of Science ®Google Scholar
• Manson JAE, Aragaki AK, Rossouw JE, WHI Investigators, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women's Health Initiative Randomized Trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• Papadakis G, Hans D, Gonzalez-Rodriguez E, et al. The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal. J Clin Endocrinol Metab 2016;101:5004–11
   PubMed Web of Science ®Google Scholar
• Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric 2017;20:306–12
   PubMed Web of Science ®Google Scholar
• Voelker R. Framingham at 70: What We’ve Learned About Women and Heart Disease. JAMA 2018;319:2259–60
   Google Scholar
• Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243–51
   PubMed Web of Science ®Google Scholar
• Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 1989;3:427–33
   PubMed Web of Science ®Google Scholar
• Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995;25:305–13
   PubMed Web of Science ®Google Scholar
• Amigoni S, Morelli P, Parazzini F, Chatenoud L. Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy. Maturitas 2000;34:25–32
   PubMed Web of Science ®Google Scholar
• Mercuro G, Zoncu S, Saiu F, et al. Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas 2004;47:131–8
   PubMed Web of Science ®Google Scholar
• Barton M, Meyer MR, Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits? Arterioscler Thromb Vasc Biol 2007;27:1669–72
   PubMed Web of Science ®Google Scholar
• Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003;7:1–94
   PubMedGoogle Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; 3347:f5680
   PubMed Web of Science ®Google Scholar
• Gerber LM, Sievert LL, Warren K, Pickering TG, Schwartz JE. Hot flashes are associated with increased ambulatory systolic blood pressure. Menopause 2007;14:308–15
   PubMed Web of Science ®Google Scholar
• Preston RA, White WB, Pitt B, et al. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797–804
   PubMed Web of Science ®Google Scholar
• White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979–84
   PubMed Web of Science ®Google Scholar
• Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002;15:816–22
   PubMed Web of Science ®Google Scholar
• Cannoletta M, Cagnacci A. Modification of Blood Pressure in Postmenopausal Women: role of Hormone Replacement Therapy. Int J Women’s Health 2014;6:745–57
   PubMedGoogle Scholar
• Gambacciani M, Rosano G, Cappagli B, et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011;14:18–24
   PubMed Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric 2016;19:349–56
   PubMed Web of Science ®Google Scholar